BioCentury
ARTICLE | Clinical News

Xtandi timeline speeds up in Phase III non-metastatic CRPC trial

June 16, 2017 5:09 AM UTC

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) said they now expect to report top-line data this year from the double-blind, international Phase III PROSPER trial of Xtandi enzalutamide to treat non-metastatic castration-resistant prostate cancer (CRPC). The companies had previously expected first data in June 2019.

The partners will reduce PROSPER's target enrollment to 1,440 from 1,560. Astellas said that based on recent clinical data in non-metastatic and chemotherapy-naïve metastatic CRPC, the partners have reduced the study's target hazard ratio and now believe they will need fewer metastasis-free survival (MFS) events to power the study. PROSPER's primary endpoint measures MFS...

BCIQ Company Profiles

Astellas Pharma Inc.

Pfizer Inc.

BCIQ Target Profiles

Androgen receptor